本届ASCO年会会议亮点 口头报告(Oral Abstract Sessions 24项;Clinical Science Symposium 16项,其中包含3场特别跨领域会议):本届年会总计超过250篇口头摘要报告壁报展示(Poster Sessions):本届年会将在周六、周日和周一展示超过2500篇壁报(包括Trails inProgress)科学项目今年共有7025篇摘要被提交供年会科学计划委员会审议。
Clinical Science Symposium (Oral) -making the Cut: Decision Support Tools in Surgically Treated HPV+ Oropharyngeal Cancer 6/3/2024 3:00 PM -4:00 PM Dr. Ming Song and Dr. Shida Yan Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patient...
NSE: BIOCON) today announced that 48-week results from the HERITAGE study will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1-5. The HERITAGE study compar...
The jury is still out for what is the best biomarker, if there is any biomarker to really help us predict. There was an abstract presented at ASCO [American Society of Clinical Oncology Annual Meeting] in the clinical science symposium on the JAVELIN Renal 101 phase III trial, looking at p...
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma Petrylak Provides Insight Into Testing, Multidisciplinary Management in Prostate and...
J Clin Oncol, ASCO Ann Meet Proc 2006; 24 (18 Suppl.): 7062Fehrenbacher L, O'Neill V, Belani CP, et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib ...
ASCO Posters Reflect on Reimbursement Trends, Combination Therapies Involving Biosimilars Skylar Jeremias June 24th 2024 Two posters from the American Society of Clinical Oncology (ASCO) annual meeting look at Medicare reimbursement trends for originator and biosimilar biologics, as well as a combination ...
0058 Determination of ASCO recommended prognostic factors uPA/PAI-1 in clinical routine and the node-negative NNBC 3-Europe therapy trial - The Breastdoi:10.1016/S0960-9776(09)70103-1C. ThomssenM. VetterE. J. KantelhardtA. Geurts-Moespot...
Pal Discusses Eye-Catching ASCO GU Data in RCC FDA Approval Insights: Adjuvant Pembrolizumab in RCCLatest CME Events & Activities 26th Annual International Lung Cancer Congress® July 25-26, 2025 Register Now! The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Out...
September 7th 2024 ASCO Palliative Care Expert Panel Provides Recommendations to Integrate Health Equity Into Guideline Development By Kyle Doherty September 5th 2024 Clinically Guided Cannabis Use Helps Mitigate Symptoms Experienced by Patients With Cancer By Megan Hollasch August 1st 2024 ...